J&J looking to add structural damage data to Stelara label

Johnson & Johnson (NYSE:JNJ) presented data on Monday at the American College of Rheumatology meeting in San Diego showing subcutaneous Stelara ustekinumab met the secondary endpoint of greater inhibition of structural damage at week 24 vs. placebo in a pre-specified analysis of the Phase III PSUMMIT I and II trials to treat active psoriatic arthritis. At week 52, J&J said Stelara continued to inhibit radiographic progression. The pharma previously reported that Stelara met the primary endpoint of improving ACR20 response rates at week 24 vs. placebo in both trials. PSUMMIT I enrolled 615 patients with active psoriatic arthritis despite treatment with DMARDs and/or NSAIDs, while PSUMMIT II enrolled 312 patients with active psoriatic arthritis despite treatment with DMARDs and/or NSAIDs and/or TNF-alpha inhibitors. ...